Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 29;15:8383–8400. doi: 10.2147/IJN.S272495

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Ding et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Schematic diagram for targeted liver cancer treatment using the nano-drug TLS11a-LB@TATp-MSN/DOX. The nuclear localization peptide (TATp)-mesoporous silica nanoparticle (MSN) complex (TATp-MSN) was synthesized and mixed with doxorubicin (DOX) (I). Liposomes that carried the liver cancer-specific aptamer TLS11a (TLS11a-LB) were produced (II). The nano-drug TLS11a-LB@TATp-MSN/DOX was generated by mixing TLS11a-LB and TATp-MSN/DOX (III). (IV) After intravenous injection, TLS11a-LB@TATp-MSN/DOX was designed to be distributed via blood circulation to liver cancer tissues through TLS11a targeting (a-b), to be localized to the nuclei of the cancer cells through TATp targeting, and to release DOX (c-e).